Amgen (FRA:AMG) Forward Dividend Yield %: 2.77% (As of Jun. 27, 2026)


FRA:AMG Amgen Inc FRA:AMG
87 GF Score
Price €313.15
GF Value €308.97
Valuation Fairly Valued
! 7 Warning Signs
View Full Analysis

What is Amgen Forward Dividend Yield %?

Amgen FRA:AMG +2.20% 87 Forward Dividend Yield % is 2.77% as of Jun. 27, 2026. GuruFocus rates FRA:AMG with a GF Score™ of 87/100 and a GF Value™ of €308.97 (Fairly Valued). The stock has 7 warning signs investors should review. Among 504 Drug Manufacturers companies, Amgen ranks better than 62.1% on this metric.

As of today (2026-06-27), the Forward Annual Dividend Yield of Amgen is 2.77%.

As of today (2026-06-27), the Trailing Annual Dividend Yield of Amgen is 2.68%.

FRA:AMG's Forward Dividend Yield % is ranked better than
62.1% of 504 companies
in the Drug Manufacturers industry
Industry Median: 2.08 vs FRA:AMG: 2.77

Amgen's Dividends per Share for the three months ended in Mar. 2026 was €2.18.

During the past 12 months, Amgen's average Dividends Per Share Growth Rate was 5.80% per year. During the past 3 years, the average Dividends Per Share Growth Rate was 7.10% per year. During the past 5 years, the average Dividends Per Share Growth Rate was 8.40% per year. During the past 10 years, the average Dividends Per Share Growth Rate was 11.10% per year.

During the past 13 years, the highest 3-Year average Dividends Per Share Growth Rate of Amgen was 63.30% per year. The lowest was 7.10% per year. And the median was 12.40% per year.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.


Amgen  (FRA:AMG) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.


Amgen Forward Dividend Yield % Related Terms


FRA:AMG vs GILD, PFE, BMY: Forward Dividend Yield % Comparison

For the Drug Manufacturers - General subindustry, Amgen's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amgen Forward Dividend Yield % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Amgen's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Amgen's Forward Dividend Yield % falls into.


FRA:AMG
87GF Score
Amgen Inc FRA:AMG
Forward Dividend Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Amgen Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

Amgen Recent Full-Year* Dividend History

Amount Ex-date Record Date Pay Date Type Frequency Forex Rate
USD 2.5200002026-05-152026-05-152026-06-05Cash DividendquarterlyUSD:EUR 0.856000
USD 2.5200002026-02-132026-02-132026-03-06Cash DividendquarterlyUSD:EUR 0.846000
USD 2.3800002025-11-212025-11-212025-12-12Cash DividendquarterlyUSD:EUR 0.865000
USD 2.3800002025-08-222025-08-222025-09-12Cash DividendquarterlyUSD:EUR 0.859000

* GuruFocus has an internal rule that if the most recent dividend payment frequency is at least 4 times a year, then the full year will be calculated according to the frequency of payment or the one-year time frame, whichever is stricter.
* GuruFocus converts dividend currency to local traded share price currency in order to calculate dividend yield. Please refer to the last column "Forex Rate" in the above table.

Amgen's Forward Annual Dividend Yield (%) for Today is calculated as

Forward Annual Dividend Yield=Forward Full Year Dividend/Current Share Price
=8.62848/313.15
=2.76 %

Current Share Price is €313.15.
Amgen's Dividends per Share for the forward twelve months is calculated as €2.15712 * 4 = €8.62848.

Amgen's Trailing Annual Dividend Yield (%) for Today is calculated as

Trailing Annual Dividend Yield=Most Recent Full Year Dividend/Current Share Price
=8.39216/313.15
=2.68 %

Current Share Price is €313.15.
Amgen's Dividends per Share for the trailing twelve months (TTM) ended in Today is €8.39216.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Forward Dividend Yield % of 2.77% mean?
Amgen (FRA:AMG) has a Forward Dividend Yield % of 2.77% as of Jun. 27, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Amgen and its competitors. According to the industry distribution chart, Amgen ranks #191 out of 504 companies in the Drug Manufacturers industry, placing it in the top 37.9%.
Is Amgen's Forward Dividend Yield % too high?
Amgen's current Forward Dividend Yield % is 2.77%. The Drug Manufacturers industry median Forward Dividend Yield % is 2.08. Amgen's value of 2.77% is 33.2% above this industry median. Based on the distribution chart, Amgen ranks #191 out of 504 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Amgen has a GF Score™ of 87/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Amgen's Forward Dividend Yield % compare to GILD and PFE?
According to the Drug Manufacturers industry distribution chart, Amgen ranks #191 out of 504 companies for Forward Dividend Yield %. This puts Amgen in the upper half of its industry. The industry median Forward Dividend Yield % is 2.08. Amgen's value of 2.77% is 33.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Drug Manufacturers company?
The median Forward Dividend Yield % among Drug Manufacturers companies is 2.08, based on 504 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Amgen's current Forward Dividend Yield % of 2.77% is 33.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Amgen and its competitors. For the Drug Manufacturers industry, the median Forward Dividend Yield % is 2.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amgen's current Forward Dividend Yield % is 2.77%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amgen stock overvalued right now?
Based on GuruFocus' analysis, Amgen (FRA:AMG) is currently considered Fairly Valued. The stock's GF Value™ is €308.97, compared to a current price of €313.15 — trading 1.4% above its estimated fair value. The current Forward Dividend Yield % is 2.77% and 33.2% above the Drug Manufacturers industry median of 2.08. Amgen's overall GF Score™ is 87/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Amgen (FRA:AMG), the current Forward Dividend Yield % is 2.77% as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Amgen (FRA:AMG) Overvalued in 2026?

Based on GuruFocus' analysis, Amgen stock appears to be overvalued. The current stock price of €313.15 is trading 1.4% above its estimated GF Value™ of €308.97. GuruFocus considers Amgen to be Fairly Valued.

Key valuation signals for FRA:AMG:

  • Forward Dividend Yield %: 2.77%
  • GF Value™: €308.97 vs. price of €313.15 (1.4% above fair value)
  • GF Score™: 87/100 with 7 warning signs
  • Industry Position: 33.2% above the Drug Manufacturers median (#191 of 504)

No single metric tells the full story. See the FRA:AMG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Amgen Business Description

Address One Amgen Center Drive, Thousand Oaks, CA, USA, 91320-1799
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
87GF Score

Get the complete analysis for FRA:AMG

Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€313.15
Price
€308.97
GF Value